difference in the tafenoquine mean IC 50 values between the three areas (P ϭ 0.111). Tafenoquine is more active in vitro than primaquine, wherever the area. Tafenoquine exerts a blood schizonticidal activity 4 to 100 times higher than that of primaquine in the Plasmodium berghei and Plasmodium yoelii mouse model (9) . Tafenoquine had a half-life that is more than 50 times longer than that of primaquine (3, 5) . The difference in kinetics results in more prolonged, high concentrations of tafenoquine in the blood. These properties permit weekly dosing for prophylaxis and short-term or single-dose therapy for radical cure.
Only 3.5% of the variation of response to tafenoquine is explained by response variation to primaquine. The coefficients of determination, r 2 , ranging from 0.001 to 0.113, are too weak to consider that cross-resistance may exist between tafenoquine and standard antimalarial drugs. Since correlation analysis provides an insight into the mode of action and crosssusceptibilities between different drugs, these data may be seen as an indication of the relative independence of tafenoquine from the susceptibility of P. falciparum to standard antimalarial drugs.
In conclusion, these data permit definition of the baseline of in vitro susceptibility to tafenoquine before its use and will allow the monitoring of its resistance or its reduced susceptibility when tafenoquine will be commonly used. Given its greater schizonticidal activity, tafenoquine is a promising candidate as a short treatment for P. falciparum and Plasmodium vivax malaria. However, the potential side effects of tafenoquine, such as the production of methemoglobin and the risk of hemolysis in glucose-6-phosphate dehydrogenase-deficient patients, have to be taken into consideration (14) . The cutoff values, defined statistically (Ͼ2 standard deviations above the mean and/or after correlation with clinical failures) for in vitro resistance or reduced susceptibility were as follows: chloroquine, 100 nM; quinine, 800 nM; mefloquine, 30 nM; halofantrine, 6 nM; amodiaquine, 80 nM; artesunate, 10.5 nM; atovaquone, 1,900 nM; cyloguanil, 500 nM; and pyrimethamine, 2,000 nM. The cutoff values for in vitro reduced susceptibility to tafenoquine, primaquine, and doxycycline have not yet been determined (ND).
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